These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29719161)

  • 1. Patient centric drug product design in modern drug delivery as an opportunity to increase safety and effectiveness.
    Stegemann S
    Expert Opin Drug Deliv; 2018 Jun; 15(6):619-627. PubMed ID: 29719161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining Patient Centric Pharmaceutical Drug Product Design.
    Stegemann S; Ternik RL; Onder G; Khan MA; van Riet-Nales DA
    AAPS J; 2016 Sep; 18(5):1047-1055. PubMed ID: 27317470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes - A proposed roadmap.
    Stegemann S; Sheehan L; Rossi A; Barrett A; Paudel A; Crean A; Ruiz F; Bresciani M; Liu F; Shariff Z; Shine M; Schmelzer C; Pense-Lheritier AM
    Eur J Pharm Biopharm; 2022 Aug; 177():81-88. PubMed ID: 35718077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An industrial perspective on the design and development of medicines for older patients.
    Page S; Coupe A; Barrett A
    Int J Pharm; 2016 Oct; 512(2):352-354. PubMed ID: 27001530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organ-based drug delivery.
    Alsaggar M; Liu D
    J Drug Target; 2018; 26(5-6):385-397. PubMed ID: 29419330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.
    Lopez FL; Ernest TB; Tuleu C; Gul MO
    Expert Opin Drug Deliv; 2015; 12(11):1727-40. PubMed ID: 26165848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards better understanding of patient centric drug product development in an increasingly older patient population.
    Stegemann S
    Int J Pharm; 2016 Oct; 512(2):334-342. PubMed ID: 26807529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development.
    Yang W; Bhattachar SN; Patel PJ; Landis M; Patel D; Reid DL; Duvnjak Romic M
    Drug Discov Today; 2021 Mar; 26(3):713-723. PubMed ID: 33333320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a preliminary review of scientific evidence for appropriateness of preparations, dosage forms and other product design elements for older adult patients.
    Messina R; Becker R; van Riet-Nales DA; Stegemann S
    Int J Pharm; 2015 Jan; 478(2):822-8. PubMed ID: 25445516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-centered drug delivery and its potential applications for unmet medical needs.
    Park C; Meghani NM; Amin HH; Nguyen VH; Lee BJ
    Ther Deliv; 2017 Aug; 8(9):775-790. PubMed ID: 28825393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heuristics for designing user-centric drug products: Lessons learned from Human Factors and Ergonomics.
    Feufel MA; Rauwolf G; Meier FC; Karapinar-Çarkit F; Heibges M
    Br J Clin Pharmacol; 2020 Oct; 86(10):1989-1999. PubMed ID: 31663157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Printed Drug-Delivery Systems for Improved Patient Treatment.
    Sandler N; Preis M
    Trends Pharmacol Sci; 2016 Dec; 37(12):1070-1080. PubMed ID: 27992318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.
    Menditto E; Orlando V; De Rosa G; Minghetti P; Musazzi UM; Cahir C; Kurczewska-Michalak M; Kardas P; Costa E; Sousa Lobo JM; Almeida IF
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31947888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and opportunities in the design of age-appropriate drug products.
    Stegemann S
    Z Gerontol Geriatr; 2012 Aug; 45(6):479-84. PubMed ID: 22806640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of medication administration errors with transdermal patches.
    Lampert A; Seiberth J; Haefeli WE; Seidling HM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1101-14. PubMed ID: 24921682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery for optimised products: from product life-cycle management to first-generation product concepts.
    Bhatt PP
    Expert Opin Drug Deliv; 2005 Jan; 2(1):1-2. PubMed ID: 16296731
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches - a PEARRL review.
    Ditzinger F; Price DJ; Ilie AR; Köhl NJ; Jankovic S; Tsakiridou G; Aleandri S; Kalantzi L; Holm R; Nair A; Saal C; Griffin B; Kuentz M
    J Pharm Pharmacol; 2019 Apr; 71(4):464-482. PubMed ID: 30070363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexity perplexity: a systematic review to describe the measurement of medication regimen complexity.
    Paquin AM; Zimmerman KM; Kostas TR; Pelletier L; Hwang A; Simone M; Skarf LM; Rudolph JL
    Expert Opin Drug Saf; 2013 Nov; 12(6):829-40. PubMed ID: 23984969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucoadhesive therapeutic compositions: a patent review (2011-2014).
    Laffleur F
    Expert Opin Ther Pat; 2016; 26(3):377-88. PubMed ID: 26796750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products.
    Cristofoletti R; Rowland M; Lesko LJ; Blume H; Rostami-Hodjegan A; Dressman JB
    J Pharm Sci; 2018 Oct; 107(10):2519-2530. PubMed ID: 29935299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.